An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).
Axel Hauschild(University Hospital Schleswig-Holstein), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Patricia Haney(GlaxoSmithKline (United States)), Salvador Martín‐Algarra(Clinica Universidad de Navarra), Eckhart Kaempgen(Comprehensive Cancer Center Erlangen), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Beloo Mirakhur(GlaxoSmithKline (United States)), Wilson H. Miller(Jewish General Hospital), Thomas Jouary(Hôpital Saint-André), Mary Guckert(GlaxoSmithKline (United States)), Jean‐Jacques Grob(Aix-Marseille Université), Cornelia Mauch(University Hospital Cologne), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Ruth Swann(Karolinska University Hospital), Bogusława Karaszewska(State University of Applied Sciences in Konin), Christian U. Blank(The Netherlands Cancer Institute), Michael Millward(University of Western Australia), Lev Demidov(Heidelberg University), Vicki Goodman, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)
Cited by 112
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k